Novel Therapeutic Strategies for Delirium in Patients With Cancer: A Preliminary Study.
作者信息
Tanimukai Hitoshi, Tsujimoto Hiroshi, Matsuda Yoshinobu, Tokoro Akihiro, Kanemura Seitetsu, Watanabe Motoo, Tsujio Ichiro, Maeda Isseki, Takei Kiyozumi, Nakajima Shinichiro, Taira Toshihiro, Tokuyama Madoka, Kai Toshihiro, Okamoto Yoshiaki, Goya Sho, Kashiwagi Yujiro
机构信息
Department of Psychiatry, Osaka University Health Care Center, Toyonaka, Japan Oncology Center, Osaka University Hospital, Suita, Japan
Department of Psychiatry, Kansai Rosai Hospital, Amagasaki, Japan.
出版信息
Am J Hosp Palliat Care. 2016 Jun;33(5):456-62. doi: 10.1177/1049909114565019. Epub 2014 Dec 30.
To compare the efficacy of antipsychotics (APs) for delirium treatment in patients with cancer, 27 patients treated with 1 of the 4 APs, haloperidol (HPD), risperidone (RIS), olanzapine (OLZ), and quetiapine (QTP), were divided into 2 groups: long half-life (T1/2; HPD, RIS, and OLZ) versus short T1/2 (QTP) or the multiacting receptor-targeted APs (MARTAs; OLZ and QTP) versus the non-MARTA (HPD and RIS). The symptom severity was evaluated by the memorial delirium rating scale (MDAS) on days 0, 3, and 7 following intervention. Significant improvements in total MDAS scores were found in all groups on day 3. However, on day 7, only the short T1/2 group and MARTA group showed significant improvement. Consideration of an AP's pharmacological properties may be helpful for improving the outcomes of pharmacological delirium intervention in patients with cancer.
Zotero 插件